Suchergebnisse
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.03 per share a year ago. These figures
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance Biopharma TBPH reported second-quarter 2026 adjusted earnings of 19 cents per share, matching the Zacks Consensus Estimate. In the year-ago quarter, the company had incurred an adjusted